Q2 2024 13F Holders as of 30 Jun 2024
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
30,284,111
-
Total 13F shares
-
31,463,055
-
Share change
-
+101,031
-
Total reported value
-
$1,436,820,755
-
Put/Call ratio
-
6.3%
-
Price per share
-
$45.70
-
Number of holders
-
149
-
Value change
-
-$1,911,760
-
Number of buys
-
83
-
Number of sells
-
56
Institutional Holders of Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KROS) as of Q2 2024
As of 30 Jun 2024,
Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KROS) was held by
149 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
31,463,055 shares.
The largest 10 holders included
FMR LLC, BlackRock Inc., VANGUARD GROUP INC, ALKEON CAPITAL MANAGEMENT LLC, Darwin Global Management, Ltd., ORBIMED ADVISORS LLC, STATE STREET CORP, PRICE T ROWE ASSOCIATES INC /MD/, BRAIDWELL LP, and Jefferies Financial Group Inc..
This page lists
150
institutional shareholders reporting positions in this security
for the Q2 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.